PD Dr. Naiba Nabieva

Department of Obstetrics and Gynaecology Medizinische Fakultät Professur für Translationale Frauenheilkunde und Geburtshilfe

Correction to: Comparative assessment of breast volume using a smartphone device versus MRI (Breast Cancer, (2025), 32, 1, (166-176), 10.1007/s12282-024-01647-6) (2025) Behrens A, Hübner H, Häberle L, Stamminger M, Zint D, Heindl F, Emons J, et al. Journal article, Erratum Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole (2024) Fasching P, Hack C, Nabieva N, Maass N, Aktas B, Kümmel S, Thomssen C, et al. Journal article Comparative assessment of breast volume using a smartphone device versus MRI (2024) Behrens A, Hübner H, Häberle L, Stamminger M, Zint D, Heindl F, Emons J, et al. Journal article CDK4/6 Inhibitors—Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer (2023) Nabieva N, Fasching P Journal article, Review article MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients (2022) Hübner H, Häberle L, Müller V, Schrader I, Lorenz R, Forstbauer H, Fink V, et al. Journal article Endocrine treatment for breast cancer patients revisited—history, standard of care, and possibilities of improvement (2021) Nabieva N, Fasching P Journal article, Review article Corrigendum to “Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany” (The Breast (2020) 54 (88–95), (S0960977620301648), (10.1016/j.breast.2020.08.011)) (2021) Schneeweiss A, Ettl J, Lüftner D, Beckmann M, Belleville E, Fasching P, Fehm TN, et al. Journal article, Erratum Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany (2020) Schneeweiss A, Ettl J, Lüftner D, Beckmann M, Belleville E, Fasching P, Fehm TN, et al. Journal article Influence of the Family Anamnesis of Breast or Ovarian Cancer on the pathological Complete Remission and the Prognosis in Patients with Breast Cancer after neoadjuvant Chemotherapy (2020) Gaß P, Haberle L, Hein A, Jud S, Lux MP, Hack C, Emons J, et al. Conference contribution Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients (2020) Hack C, Häberle L, Brucker SY, Janni W, Volz B, Löhberg C, Hartkopf AD, et al. Journal article